Asthma and COPD Therapies: World Market 2013-2023

  • September 2013
  • -
  • Visiongain
  • -
  • 360 pages

Report Details
New study reveals sales potential of this large, expanding market

See what the future holds for asthma and COPD therapies. Visiongain's report gives you drug revenue predictions to 2023. You find data, trends, opportunities and commercial prospects.

That new study lets you assess forecasted sales at overall world market, submarket, product, company and national level. You see why the asthma and COPD market will grow, as we predict.

In our investigation you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses, R&D and commercial developments. You receive 114 tables, 210 charts and four research interviews, including two with executives from GSK.

The following sections highlight what you discover in the report.

Prospects for submarkets and products

In addition to analyses of the overall world market, you see revenue forecasting of three world-level submarkets to 2023:
• Bronchodilators (Mono-therapy)
• Anti-inflammatory drugs
• Combination drugs

Also, you see how 19 leading drugs - including Seretide/Advair, Singulair, Spiriva, Symbicort and Pulmicort - can perform to 2023.

Prospects for leading countries shown to 2023

Developments worldwide will influence the market, especially fast-rising demand in emerging countries. There will be many opportunities for asthma and COPD therapies.

You discover revenue forecasts to 2023 for eleven national markets:
• US
• Japan
• Germany, France, UK, Italy and Spain (EU5 nations)
• India
• China
• Brazil
• Russia.

This decade, revenues from India and China will be among the fastest growing worldwide. In particular, product launches from 2013 onwards will benefit regional and national markets.

Research and development activities

What's happening in the R&D drug pipeline? You see developmental trends there:
• Monoclonal antibodies
• Ultra-Long Acting Beta-2 Agonists
• Muscarinic Antagonist Beta-2 Agonists
• Anti-leukotriene agents
• LAMA/LABA Combinations
• Developments in delivery systems
• Developments in telehealth

Discover how technological progress changes the sector. Our investigation explains, bringing together many issues.

Prominent issues affecting the asthma and COPD market

Our study lets you assess industry trends and outlooks worldwide from 2013. As the work shows, many issues affect the industry and market:
• An increasingly mature asthma market
• Patient adherence
• Patient management techniques
• Reimbursement, regulations, patent expiries and generic competition
• An increasingly segregated patient population

You see discussions of technological, commercial and economic matters, with emphasis on organisations competing in the industry.

Discussions of leading companies and prospects for market growth

What will happen next? The pharmaceutical industry will improve treatments for asthma and COPD and increase revenues there from 2013 to 2023. The R&D pipeline is strong. Our work shows you what technologies and organisations hold greatest potential. See profiles of seven leading companies, including these:
• GSK
• Boehringer Ingelheim
• Merck
• AstraZeneca

In general, a company profile gives you the following information:
• Discussion of a company's activities and outlook
• Assessment of its developments - mergers and acquisitions (M&A), new products, and collaborations.
• Forecasting of asthma and COPD drug revenues to 2023

Overall world revenue for that market area will reach $34.51bn in 2013, our report forecasts. Ageing populations, educational initiatives, improved drug delivery and new formulations will increase sales of asthma and COPD therapies.

Nine ways Asthma and COPD Therapies: World Market 2013-2023 benefits you

In particular, then

Table Of Contents

1. Executive Summary

1.1 Key Findings
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods

2. Introduction to Asthma and COPD Therapies

2.1 Introduction
2.2 Overview of Respiratory Disorders
2.3 What is Asthma?
2.3.1 Symptoms of Asthma
2.3.2 Causes and Triggers of Asthma
2.3.3 Trends in Asthma Prevalence
2.3.4 Guidelines for Asthma Treatment
2.3.5 Economic Burden of Asthma
2.3.6 Current Treatments for Asthma
2.3.7 Delivery Method - Types of Inhaler
2.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
2.4.1 What are the Signs and Symptoms of COPD?
2.4.2 Management of COPD
2.4.3 Guidelines for COPD Management
2.4.4 Trends in COPD Prevalence
2.4.5 Economic Burden of COPD
2.5 Major Drug Classes in Treating Respiratory Diseases
2.5.1 Bronchodilators
2.5.1.1 Beta-2 (Adrenoreceptor) Agonists
2.5.1.2 Anticholinergics
2.5.2 Anti-Inflammatory Drugs
2.5.2.1 Corticosteroids (ICS)
2.5.2.2 Leukotriene Inhibitors
2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
2.5.3 Combination Drugs
2.5.4 Antihistamines

3. The Asthma and COPD Therapies Market 2013-2023

3.1 The Global Respiratory Market
3.1.1 Growing Market for Respiratory Treatments
3.1.2 The World Respiratory Market: Breakdown by Disorders
3.2 The World Asthma and COPD Therapies Market
3.2.1 Growing Market for Asthma and COPD Drug Treatments
3.2.2 The World Asthma and COPD Therapies Market: Market Shares Forecast by Therapy Area 2013-2023
3.2.3 Asthma and COPD Therapies: World Sales Forecast by Therapy Area 2013-2017
3.2.4 Asthma and COPD Therapies: World Sales Forecast by Therapy Area 2018-2023
3.2.5 The World Asthma Therapies Market
3.2.5.1 The World Asthma Therapies Market: Sales Forecast 2013-2017
3.2.5.2 The World Asthma Therapies Market: Sales Forecast 2018-2023
3.2.6 The World COPD Therapies Market
3.2.6.1 The World COPD Therapies Market: Sales Forecast 2013-2017
3.2.6.2 The World COPD Therapies Market: Sales Forecast 2018-2023
3.2.7 World Asthma and COPD Therapies Market: Market Shares by Drug Class, 2012
3.2.8 World Asthma and COPD Therapies Market: Market Share Forecasts by Drug Class 2013-2023
3.2.9 Asthma and COPD Therapies: World Sales Forecast by Drug Classes 2013-2017
3.2.10 Asthma and COPD Therapies: World Sales Forecast by Drug Class 2018-2023
3.2.11 Global Asthma and COPD Therapies Market: Drivers and Restraints, 2013-2023

4. Bronchodilators Mono-therapy Drugs: World Market, 2013-2023

4.1 Introduction
4.2 The World Bronchodilators Mono-Therapy Market: Market Shares by Type
4.3 The World Bronchodilators Mono-Therapy Market: Market Shares Forecast by Type 2013-2023
4.4 The World Bronchodilators Mono-Therapy Market: Sales Forecast by Type 2013-2017
4.5 The World Bronchodilators Mono-Therapy Market: Sales Forecast by Type 2018-2023
4.6 The World Short-Acting Beta-2 Agonists (SABA) Market
4.6.1 The World Short-Acting Beta-2 Agonist (SABA) Market: Market Shares by Leading Drugs, 2012
4.6.2 The World Short-Acting Beta-2 Agonist (SABA) Market: Market Share Forecast by Leading Drugs, 2013-2023
4.6.3 The World Short-Acting Beta 2 Agonist (SABA) Market: Sales Forecast by Leading Drugs 2013-2017
4.6.4 The World Short-Acting Beta-2 Agonist (SABA) Market: Sales Forecast by Leading Drugs 2018-2023
4.6.5 Ventolin
4.6.5.1 Ventolin: World Sales, 2012
4.6.5.2 Ventolin: World Sales Forecast 2013-2017
4.6.5.3 Ventolin: World Sales Forecast 2018-2023
4.6.6 ProAir
4.6.6.1 ProAir: World Sales, 2012
4.6.6.2 ProAir: World Sales Forecast 2013-2017
4.6.6.3 ProAir: World Sales Forecast 2018-2023
4.6.7 Xopenex
4.6.7.1 Xopenex: World Sales, 2012
4.6.7.2 Xopenex: World Sales Forecast 2013-2023
4.6.7.3 Xopenex: World Sales Forecast 2018-2023
4.6.8 Proventil
4.6.8.1 Proventil: World

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely ...

Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • Dec 2014
  • by BCC Research

REPORT HIGHLIGHTS The global market for cancer vaccines was about $4.5 billion in 2013. This market reached about $4.0 billion in 2014 and is expected to reach $4.3 billion in 2019, registering a compound ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.